Retrospective Investigation of the Impacts of Prognosis for Nasopharyngeal Carcinoma Patients
Stage-specified Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Locoregionally-advanced Nasopharyngeal Carcinoma - A Retrospective, Population-based Study
1 other identifier
observational
12,206
0 countries
N/A
Brief Summary
To investigate whether the additional induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) was able to improve overall survival (OS) and disease-free survival (DFS), and to clarify if stage-specified chemoradiotherapy regimens benefit the most for locoregionally advanced NPC.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 1998
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 1998
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2015
CompletedFirst Submitted
Initial submission to the registry
November 11, 2015
CompletedFirst Posted
Study publicly available on registry
November 13, 2015
CompletedNovember 13, 2015
November 1, 2015
15.4 years
November 11, 2015
November 12, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
overall survival
up to 10 years
Secondary Outcomes (1)
disease-free survival
up to 10 years
Study Arms (2)
CCRT group
Locoregionally advanced nasopharyngeal carcinoma patients received concurrent chemoradiotherapy
IC+CCRT group
Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and concurrent chemoradiotherapy
Interventions
Locoregionally advanced nasopharyngeal carcinoma patients received platinum-based/non-platinum based concurrent chemoradiotherapy.
Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and platinum-based/non-platinum based concurrent chemoradiotherapy.
Eligibility Criteria
firstly diagnosed NPC in SYSUCC from Jan 1st, 1998 to Jun 1st, 2013
You may qualify if:
- firstly diagnosed NPC in SYSUCC from Jan 1st, 1998 to Jun 1st, 2013;
- with complete medical records;
- received radical RT.
You may not qualify if:
- distant metastasis patients at first diagnosis,
- recurrent patients,
- not finishing radiotherapy, missing medical data, death during RT, stage I or II disease,received treatment previously, or without concurrent chemoradiotherapy were excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Xia WX, Liang H, Lv X, Wang L, Ye YF, Ke LR, Xu LH, Guo X, Xiang YQ. Stage-specific concurrent chemoradiotherapy with or without induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective, population-based study. Cancer Manag Res. 2019 Nov 20;11:9813-9827. doi: 10.2147/CMAR.S179139. eCollection 2019.
PMID: 31819619DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Xiang Guo, MD, PhD
Sun Yat-sen University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- associate professor
Study Record Dates
First Submitted
November 11, 2015
First Posted
November 13, 2015
Study Start
January 1, 1998
Primary Completion
June 1, 2013
Study Completion
October 1, 2015
Last Updated
November 13, 2015
Record last verified: 2015-11